Advanced Breast Cancer Patient Selection: A Compendium of Abemaciclib Treatment

Dr. Alistair Ring dissects the data from MONARCH 2 trial where abemaciclib plus fulvestrant was compared to fulvestrant plus placebo in an endocrine-resistant HR+, HER2- MBC population.1 Reference 1. Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H.

The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA oncology. 2020 Jan 1;6(1):116-24.